Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025-FY EPS reported $1.21 revenue$1,500,000,000

FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.
Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.
Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.
Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.
2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.